APA (7th ed.) Citation

HS, Ø., T, d. M. K., AS, W., KH, B., J, S., I, J., . . . GL, G. (2024). Humoral and cellular responses to a fifth bivalent SARS-CoV-2 vaccine dose in patients with immune-mediated inflammatory diseases on tumour necrosis factor inhibitors: A prospective cohort study. The Lancet regional health. Europe, 48, 101121. https://doi.org/10.1016/j.lanepe.2024.101121

Chicago Style (17th ed.) Citation

HS, Ørbo, et al. "Humoral and Cellular Responses to a Fifth Bivalent SARS-CoV-2 Vaccine Dose in Patients with Immune-mediated Inflammatory Diseases on Tumour Necrosis Factor Inhibitors: A Prospective Cohort Study." The Lancet Regional Health. Europe 48 (2024): 101121. https://doi.org/10.1016/j.lanepe.2024.101121.

MLA (9th ed.) Citation

HS, Ørbo, et al. "Humoral and Cellular Responses to a Fifth Bivalent SARS-CoV-2 Vaccine Dose in Patients with Immune-mediated Inflammatory Diseases on Tumour Necrosis Factor Inhibitors: A Prospective Cohort Study." The Lancet Regional Health. Europe, vol. 48, 2024, p. 101121, https://doi.org/10.1016/j.lanepe.2024.101121.